NVNI vs FULC Comparison

Nvni Group Ltd, through its existing subsidiary companies, operates business-to-business software-as-a-service (B2B SaaS) products in Brazil, serving a diversified customer base of small and mid-sized enterprises across vertical markets. The Group's core business activity is providing a SaaS platform model focused on the software delivery method of cloud-based software applications to its customers. The Group generates revenues and profits from SaaS platform subscription services, data analytics services, set-up and other services. The Group has a single operating and reportable segment, multi-vertical SaaS solution model. The Group operates and generates revenue from Brazil.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.